Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
Congrats to Dr. Sarah Merriam on the @SocietyGIM Scholarship in Medical Education Award! π From curriculum development in women's health to mentoring residents and teaching future clinician-educators, her impact on medical education is profound. #PittMed#SGIM26#MedEd